Pembrolizumab Combinations Mexico: COFEPRIS Market Access & Clinical Insights

Key Takeaways

• Regulatory authorization: COFEPRIS granted marketing approval for pembrolizumab (registration 277M2016 SSA IV) based on KEYNOTE-006 data showing median overall survival of 32.7 months versus 15.9 months with ipilimumab.
• Clinical efficacy: The phase 3 trial demonstrated objective response rates of 33–34% with pembrolizumab versus 12% with ipilimumab, with lower rates of grade 3–4 treatment-related adverse events (10–13% versus 20%).
• Market access: COFEPRIS included pembrolizumab in its 2017 innovative medicines initiative, achieving an estimated 53% cost reduction compared to pre-approval import pricing.
• Patient population: The approval covers treatment-naïve and previously treated patients with unresectable stage III or metastatic melanoma regardless of PD-L1 status.

What is the COFEPRIS regulatory framework for pembrolizumab?

The Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) regulates pembrolizumab under registration 277M2016 SSA IV. The agency approved the programmed death receptor-1 (PD-1) inhibitor for advanced melanoma following its demonstrated efficacy in global phase 3 trials.

COFEPRIS maintains a regulatory equivalence agreement with stringent regulatory authorities including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This framework enables Mexico to recognize approvals from these agencies while maintaining independent pharmacovigilance oversight.

In 2017, COFEPRIS included pembrolizumab in its ninth innovative medicines release, part of a package of 63 new drugs addressing diseases representing 54% of mortality causes in Mexico. The commission reported that oncology treatments in this package cost 53% less than equivalent pre-approval import prices.

What clinical evidence supports the approval?

The regulatory authorization rests primarily on data from KEYNOTE-006 (NCT01866319), a randomized, open-label, phase 3 trial conducted at 87 sites across 16 countries. Merck Sharp & Dohme sponsored the study, which enrolled 834 patients with advanced melanoma.

Investigators randomized patients 1:1:1 to receive pembrolizumab 10 mg/kg every 2 weeks, pembrolizumab 10 mg/kg every 3 weeks, or ipilimumab 3 mg/kg every 3 weeks for four doses. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS).

At median follow-up of 57.7 months, pembrolizumab demonstrated:

KEYNOTE-006 Efficacy Results (Final Analysis)

Endpoint	Pembrolizumab	Ipilimumab	Hazard Ratio (95% CI)
Median overall survival	32.7 months	15.9 months	0.73 (0.61–0.88)
Median progression-free survival	8.4 months	3.4 months	0.57 (0.48–0.67)
Objective response rate	33–34%	12%	—
24-month overall survival rate	55%	43%	—

The study included patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with 66% being treatment-naïve and 34% having received one prior systemic therapy. Efficacy was consistent across PD-L1 positive and negative subgroups.

How does pembrolizumab compare to combination immunotherapy?

While pembrolizumab monotherapy is approved in Mexico, combination checkpoint blockade with nivolumab plus ipilimumab represents an alternative dual-mechanism approach. The CheckMate-067 trial (NCT01844505) demonstrated that nivolumab plus ipilimumab improved progression-free survival versus ipilimumab alone in treatment-naïve advanced melanoma patients.

Key differences between approaches include:

• Pembrolizumab monotherapy: Single-agent PD-1 inhibition with objective response rates around 33–34% and grade 3–4 adverse event rates of 10–13%
• Nivolumab plus ipilimumab: Dual checkpoint blockade (PD-1 plus CTLA-4) with higher response rates but increased toxicity; grade 3–4 adverse events occur in approximately 55–59% of patients
• Patient selection: Combination therapy is typically reserved for patients with high disease burden or rapid progression who can tolerate increased immune-related toxicity

COFEPRIS has approved both therapeutic strategies, allowing oncologists to select treatment based on individual patient characteristics, disease stage, and performance status.

What safety considerations apply to pembrolizumab use?

Pembrolizumab's mechanism—blocking PD-1 signaling to enhance T-cell anti-tumor activity—can trigger immune-related adverse events (irAEs). These require prompt recognition and management by trained oncology teams.

Common immune-mediated adverse reactions include pneumonitis, colitis, hepatitis, hypophysitis, nephritis, and endocrinopathies (hyperthyroidism, hypothyroidism). Management protocols involve corticosteroid administration and treatment interruption or discontinuation based on severity grading.

In KEYNOTE-006, the safety profile favored pembrolizumab over ipilimumab. Grade 3–4 treatment-related adverse events occurred in 13.3% of patients receiving pembrolizumab every 2 weeks, 10.1% receiving pembrolizumab every 3 weeks, and 19.9% receiving ipilimumab.

COFEPRIS requires post-marketing pharmacovigilance reporting through Mexico's established adverse event surveillance system. This monitors safety signals specific to the Mexican patient population and ensures ongoing risk-benefit assessment.

How do patients access pembrolizumab in Mexico?

Patients access pembrolizumab through COFEPRIS-regulated specialized oncology clinics and hospital pharmacies. The drug is available via prescription from qualified oncologists who assess eligibility based on histologically confirmed unresectable or metastatic melanoma.

Coverage pathways include:

• IMSS (Instituto Mexicano del Seguro Social): Public insurance for formal sector workers; formulary inclusion varies by treatment line and indication
• ISSSTE (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado): Coverage for government employees and dependents
• Private insurance: Reimbursement policies vary by plan; prior authorization typically required
• Out-of-pocket: Pricing through regulated private pharmacies

The 2017 innovative medicines initiative reduced costs for oncology treatments, though exact current pricing requires verification with individual providers. Geographic access varies, with specialized oncology centers concentrated in major metropolitan areas including Mexico City, Guadalajara, and Monterrey.

What is the future outlook for melanoma immunotherapy in Mexico?

Mexico's melanoma treatment environment continues to evolve through expanded clinical trial access and updated reimbursement policies. COFEPRIS has authorized trials evaluating novel combinations including mRNA vaccine V940 (mRNA-4157) in combination with pembrolizumab for high-risk melanoma.

Real-world evidence collection within Mexican clinical settings will inform long-term efficacy and safety profiles specific to the local patient population. COFEPRIS continues to evaluate new indications for pembrolizumab, including potential expansions to adjuvant melanoma therapy and other solid tumors.

Stakeholder priorities include expanding geographic access to specialized oncology centers, developing standardized irAE management protocols for Mexican healthcare settings, and monitoring competitive developments in the PD-1 inhibitor market including potential biosimilar entry.

Frequently Asked Questions

Primary Sources

1. U.S. Food and Drug Administration. Approval Package for Keytruda (pembrolizumab) Application Number 125514. Approval Date: September 4, 2014.
2. Merck & Co., Inc. Merck Receives Accelerated Approval of KEYTRUDA (pembrolizumab). Press Release, September 4, 2014.
3. ClinicalTrials.gov. Study to Evaluate the Safety and Efficacy of Pembrolizumab Versus Ipilimumab in Participants With Advanced Melanoma (KEYNOTE-006). NCT01866319.
4. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet. 2017;390(10105):1853-1862.
5. ClinicalTrials.gov. Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067). NCT01844505.
6. Medicamentos PLM. KEYTRUDA (pembrolizumab) Solución. COFEPRIS Registration 277M2016 SSA IV.
7. Federación Mexicana de Diabetes. Aprueban 63 medicamentos innovadores. April 19, 2017. COFEPRIS 9th Innovative Medicines Release.
8. U.S. National Library of Medicine. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2015;372(26):2521-2532. DOI: 10.1056/NEJMoa1503093.